Reducing VTE
February 21, 2013
DABIGATRAN etexilate mesylate
may help to reduce the risk of
recurrent venous
thromboembolism (VTE) according
to trial results published in the New
England Journal of Medicine.
VTE is the third most common
cardiovascular disorder after heart
disease and stroke, and consists of
two related conditions caused by
blood clots: deep vein thrombosis
and pulmonary embolism.
The trials involved a combined
4,199 patients, with the first
RE-MEDY trial finding that
treatment with dabigatran 150mg
twice daily was non-inferior to
warfarin (p=0.01) in preventing
recurrent VTE, including VTErelated
death.
The second trial, RE-SONATE,
demonstrated dabigatran was
superior to placebo for the
prevention of first recurrent or fatal
VTE with a risk reduction of 92
percent during the treatment
period (p<0.001).
Lower event rates were reported
across all secondary efficacy
endpoints for dabigatran over
placebo.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Feb 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Feb 13
